Roxybond is a drug owned by Protega Pharmaceuticals Inc. It is protected by 2 US drug patents filed from 2017 to 2019 out of which none have expired yet. Based on its patents and exclusivities, its generic launch date is estimated to be Aug 12, 2028. Details of Roxybond's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US7955619 | Abuse resistant drugs, method of use and method of making |
Aug, 2028
(2 years from now) | Active |
| US10314788 | Pharmaceutical compositions configured to deter dosage form splitting |
Aug, 2028
(2 years from now) | Active |
A patent's expiry date may change depending upon legal activities going on that patent. Critical
activities like
abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease
the life of a
patent hence affecting its expiry date and in turn affecting the generic launch date of that drug.
Tracking these
ongoing activities on a patent application helps to keep an eye on the latest developments in the
patent process of
the drug which can give an idea of how early a drug's generic could be available. The next section
provides a list of
recent legal activities on Roxybond's patents.
Latest Legal Activities on Roxybond's Patents
Given below is the list of recent legal activities going on the following patents of Roxybond.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Correspondence Address Change | 18 Aug, 2024 | US7955619 |
| Correspondence Address Change | 21 Dec, 2023 | US7955619 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 14 Jun, 2022 | US10314788 |
| Payment of Maintenance Fee, 12th Yr, Small Entity | 08 Jun, 2022 | US7955619 |
| Email Notification | 20 Oct, 2020 | US7955619 |
| Change in Power of Attorney (May Include Associate POA) | 20 Oct, 2020 | US7955619 |
| Correspondence Address Change | 15 Oct, 2020 | US7955619 |
| Email Notification | 08 Sep, 2020 | US10314788 |
| Change in Power of Attorney (May Include Associate POA) | 08 Sep, 2020 | US10314788 |
| Correspondence Address Change | 03 Sep, 2020 | US10314788 |
FDA has granted several exclusivities to Roxybond. Till the time
these exclusivities
are active, no other company can market a generic or bioequivalent version of Roxybond, regardless of the status of it's patents. These exclusivities hence play a crucial role in
delaying the generic
launch. Given below are details of the exclusivities granted to
Roxybond.
Exclusivity Information
Roxybond holds 1 exclusivities. All of its exclusivities have expired in 2020. Details of Roxybond's exclusivity codes and their expiration dates are given below.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Apr 20, 2020 |
US patents provide insights into the exclusivity only within the United States, but
Roxybond is protected by patents in multiple countries.
Understanding
the full scope
of patent protection is crucial in strategizing market entry. By looking at the broader patent
landscape, you can
identify markets with weaker patent protection which could be ideal generic entry points. The
following section offers
details on Roxybond's family patents as well as insights into
ongoing legal events
on those patents.
Roxybond's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Roxybond's generic launch date based on the last expiry date of its patents and exclusivities combined is estimated to be Aug 12, 2028 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Roxybond Generic API suppliers:
Oxycodone Hydrochloride is the generic name for the brand Roxybond. 26 different companies have already filed for the generic of Roxybond, with Epic Pharma Llc having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Roxybond's generic
Alternative Brands for Roxybond
There are several other brand drugs using the same active ingredient (Oxycodone Hydrochloride) as Roxybond. Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.
| Drug Owner | Drug Name | ||
|---|---|---|---|
| Mallinckrodt Inc |
| ||
| Pfizer |
| ||
| Purdue Pharma Lp |
| ||
| Zyla |
|
Apart from brand drugs containing the same ingredient, some generics have also been filed for Oxycodone Hydrochloride, Roxybond's active ingredient. Check the complete list of approved generic manufacturers for Roxybond
About Roxybond
Roxybond is a drug owned by Protega Pharmaceuticals Inc. Roxybond uses Oxycodone Hydrochloride as an active ingredient. Roxybond was launched by Protega in 2017.
Approval Date:
Roxybond was approved by FDA for market use on 20 April, 2017.
Active Ingredient:
Roxybond uses Oxycodone Hydrochloride as the active ingredient. Check out other Drugs and Companies using Oxycodone Hydrochloride ingredient
Dosage:
Roxybond is available in tablet form for oral use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 15MG | TABLET | Prescription | ORAL |
| 30MG | TABLET | Prescription | ORAL |
| 5MG | TABLET | Prescription | ORAL |
| 10MG | TABLET | Prescription | ORAL |